Comparative Pharmacology
Head-to-head clinical analysis: LOXITANE C versus LOXITANE IM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOXITANE C versus LOXITANE IM.
LOXITANE C vs LOXITANE IM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Loxapine, a dibenzoxazepine antipsychotic, acts primarily by blocking dopamine D2 receptors in the brain. It also exhibits affinity for serotonin 5-HT2A receptors, alpha-adrenergic, histaminergic, and muscarinic receptors, contributing to its antipsychotic and sedative effects.
LOXITANE IM (loxapine) is a dibenzoxazepine antipsychotic. Its mechanism of action is not fully established but is thought to be mediated via antagonism of central dopamine D2 and serotonin 5-HT2A receptors. It has high affinity for D2, D3, D4, and 5-HT2A receptors and low affinity for D1 receptors. It also has moderate affinity for histamine H1 and alpha1-adrenergic receptors.
10 mg orally twice daily initially; may increase by 10 mg/day every 3–4 days; usual therapeutic range 60–100 mg/day; maximum 250 mg/day.
Adults: 12.5-50 mg IM every 4-6 hours as needed, not to exceed 150 mg/day.
None Documented
None Documented
Terminal elimination half-life is 4-8 hours (mean 6 hours). Clinical context: Requires multiple daily dosing; stable plasma levels achieved by second day.
Terminal elimination half-life: 8-12 hours. Clinically, steady-state reached in 2-3 days; dosing interval based on q6-12h.
Approximately 70% renal (mainly as conjugated metabolites, <1% unchanged), 30% fecal via biliary excretion.
Primarily renal: 70% as metabolites; biliary/fecal: 30% as metabolites and unchanged drug.
Category C
Category C
Antipsychotic
Antipsychotic